- Home
- STR vs AUPH Comparison
STR vs AUPH Comparison
Compare STR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- AUPH
- Stock Information
- Founded
- STR 2016
- AUPH 1993
- Country
- STR United States
- AUPH Canada
- Employees
- STR N/A
- AUPH N/A
- Industry
- STR Oil & Gas Production
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- STR Energy
- AUPH Health Care
- Exchange
- STR Nasdaq
- AUPH Nasdaq
- Market Cap
- STR 1.4B
- AUPH 1.4B
- IPO Year
- STR N/A
- AUPH 1999
- Fundamental
- Price
- STR $18.64
- AUPH $12.18
- Analyst Decision
- STR Buy
- AUPH Strong Buy
- Analyst Count
- STR 6
- AUPH 4
- Target Price
- STR $26.80
- AUPH $12.25
- AVG Volume (30 Days)
- STR 1.1M
- AUPH 2.7M
- Earning Date
- STR 08-04-2025
- AUPH 07-31-2025
- Dividend Yield
- STR 7.50%
- AUPH N/A
- EPS Growth
- STR N/A
- AUPH N/A
- EPS
- STR 0.44
- AUPH 0.42
- Revenue
- STR $613,649,000.00
- AUPH $260,111,000.00
- Revenue This Year
- STR N/A
- AUPH $12.15
- Revenue Next Year
- STR N/A
- AUPH $18.34
- P/E Ratio
- STR $42.40
- AUPH $28.76
- Revenue Growth
- STR N/A
- AUPH 25.59
- 52 Week Low
- STR $14.58
- AUPH $5.41
- 52 Week High
- STR $25.52
- AUPH $12.32
- Technical
- Relative Strength Index (RSI)
- STR 49.30
- AUPH 78.31
- Support Level
- STR $17.98
- AUPH $11.18
- Resistance Level
- STR $18.89
- AUPH $12.10
- Average True Range (ATR)
- STR 0.52
- AUPH 0.56
- MACD
- STR 0.05
- AUPH 0.15
- Stochastic Oscillator
- STR 55.49
- AUPH 98.79
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.